1. Rapporteur Report – Track A Basic and Translational Sciences
Mathias Lichterfeld, M. D., Ph. D.
Associate Professor of Medicine
Brigham and Women’s Hospital
Harvard Medical School
no relevant conflicts of interest or other disclosures

2. The number of identical HIV-DNA sequence expansions increases over time in peripheral blood
Lee/Palmer et al, Abstract MOAA0105

3. Defective proviruses can encode for HIV-1 protein
Imamichi/Lane et al, Abstract MOPDA0102

4. HIV-specific CD8+ T cells in early treated subjects are more functionally competent
Untreated
IFN-gamma
CD8
Tetramer
Nkosi/Ndhlovu et al, Abstract TUAA0101

5. hetIL-15 Treatment Increases SIV-specific T Cells
Within the Lymph Nodes
CD8
CM9 Tetramer+
Untreated
hetIL-15
0.3
2.5
CD3+ T lymphocytes in LN
Tetramer+
Granzyme B
Ki67
Expansion
Cytotoxic
Potential
Valentin/Pavlakis et al, Abstract TUPDA0103

6. hetIL-15 Treatment Increases SIV-specific T Cells
Within the Lymph Nodes germinal center
Pre-ALT803
Post-ALT803
Webb/Sacha et al, Abstract TUPDA0104

7. Plasma viremia in SIV-infected NHP
after treatment with ART and a4/b7 antibodies or control
Fauci et al, Presentation MOSS0102

8. Viral control following a4b7 antibody infusion is
Likely mediated by cellular immune responses
Fauci et al, Presentation MOSS0102

9. Prolonged HIV-1 control after perinatal infection “The South African Baby”
HIV-1 DNA detectable at 32 days of life
Initiated AZT/3TC/LPV/r at 8.5 weeks of life
Interrupted ART after 40 weeks
3-monthly f/u
Undetectable VL after 8.75 years off ART on stored and current specimens
No protective HLA class I alleles
Weak HIV-specific T/B cell responses
5 HIV DNA copies/ million CD4 T cells
VOA negative x2
Violari/Tiemessen et al, Abstract TUPDB0106LB

10. Delayed viral rebound after treatment during hyperacute
HIV-1 infection
Participant A:
Underwent ATI after 34 months of ART
Latent reservoir size ≈200 cells prior to ATI
≈1% of individuals with a similar HIV burden may achieve lifelong ART-free remission
Henrich/Deeks et al, Abstract TUPDB0103

11. Effects of therapeutic vaccination in ART-treated
HIV patients on viral rebound kinetics
Fauci et al, Presentation MOSS0102

12. Therapeutic vaccination has no effect on viral rebound
kinetics or viral reservoir markers
Fauci et al, Presentation MOSS0102

13. Viral reservoir biomarkers represent predictors of
viral rebound kinetics
Fauci et al, Presentation MOSS0102

14. Many thanks! Nancie Archin, PhD Univ of North Carolina, Chapel Hill
Anni Winckelman, MD
Univ of Aarhus,
Denmark
Caroline Pereira
Bittencourt Passes, PhD
Institute Pasteur, Paris